

Form PTO 1449 (Modified)	- V	U.S. DEPARTMENT	OF COMMERCE EMARK OFFICE	ATTY DOCKET NO. PLOVIN-3 A		SERIAL NO		
LIST OF REFERENCES CITED BY APPLICANT			APPLICANT Eberhard NIESCHLAG et al.					
,			FILING DATE JANUARY 19, 2001		GROUP 5			
U.S. PATENT DOCUMENTS							VED VED	
EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	
es	AA	5,035,891	30JUL91	RUNKEL et al.		1		
Î	AB	5,965,552	12OCT99	BERLINER et al.				
	AC	5,855,905	05JAN99	OETTEL et al.				
	AD	4,210,644	01JUL80	EWING et al.				
	AE	5,633,242	27MAY97	OETTEL et al.		<u>·</u>		
	AF	5,583,129	10DEC96	SPONA et al.				
	AG	4,018,919	19APR77	BLACK ·				
	АН	5,811,117	22SEP98	HASHIMOTO et al.				
	Al	RE 36,247	06JUL99	PLUNKETT et al.				
AV3	AJ	5,711,962	27JAN98	CORDES et al.	_			
	AK						,	
	AL							
	AM		_		<u> </u>			
		1	' FOR	EIGN PATENT DOCUMENTS	•	•	,	
	Γ	DOCUMENT		2			TRANSLATION	
10.0		NUMBER	DATE	COUNTRY		YE		
CB	.AO	0 773 028 A1	14MAY97			<u> </u>		
<u> </u>	AP	0 696 454 A2				ļ		
	AQ	0 587 047 A2	16MAR94		<u></u>			
	AR							
<u> </u>	AS							
	AT					ļ		
	AU			•		l		
	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
OB	AW	E. NIESCHLAG et al., "Testosterone Therapy," Male Reproductive Health and Dysfunction, pp. 297-309 (1997)						
	AX	Beatrize Couzinet et al., "The Antigonadotropic Activity of Progestins (19-Nortestosterone and 19-Norprogestosterone Derivatives) Is not Mediated through the Androgen Receptor," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, No. 12, pp. 4218-4223 (1996)						
	AY	M.A. Okon et al., "A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of "period free" hormone replacement therapy," <i>Human Reproduction</i> , 31 , No. 8, pp. 2261-2265 (1998)						
05	AZ	J.F. Guerin et al., "Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens," <i>International Journal of Andrology</i> , 11 , pp. 187-199 (1988)						
Examiner Rachel M. Bennett Date Considered 2010								
*Examiner: if not in con	*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							





SHEET 2 OF 2

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE	ATTY DOCKET NO. PLOVIN-3	SERIAL NO. 09/764,149			
(Manage of the Control of the Contro			APPLICANT	09//04,149			
LIST OF	REFER	RENCES CITED BY APPLICANT	Eberhard NIESCHLAG et a				
			FILING DATE JANUARY 19, 2001	GROUP OF STOCK			
		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages,	etc.)			
			cyproterone acetate and testosterone enanthate fo	r contraception in men Human			
W	AAA	Reproduction, 13, pp. 1225-1229 (19	98)	(ER			
	445		imental Approaches," Hormone Male Contraceptio	n Andrology - Male-reproductive			
ſ	Ž	Health and Dysfunction, pp. 388-393	(1997)	0			
	AAC	F. Neuman et al., "Androgens II and a	Anti-Androgens," <i>Springer-Verlag, Berlin, Heidelbe</i>	org, pp. 436-437 (1974)			
	AAD	Fuhrmann et al., "Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of cat expression by anti-androgens," <i>J. Steroid Biochem. Mol. Biol.</i> , 42(8), p. 787 (1992)					
	AAE	K.H. Fritzemeier et al., "In Vitro and In Vivo Models to Characterize Estrogens and Antiestrogens," <i>Handbook of Experimental Pharmacology</i> , Vol. 135, pp. 6-43 (1999)					
	AAF	E. Nieschlag et al., "Testosterone in male contraception," Testosterone: action, deficiency, substitution, pp. 513-528 (1998)					
·	AAG	H.M. Behre et al., "Potential of Testosterone Buciclate for Male Contraception: Endocrine Differences between Responders and Nonresponders," <i>Journal of Clinical Endocrinology and Metabolism</i> , 80, No. 8, pp. 2394-2403 (1995)					
	AAĤ	M.C. Merrigiola et al., "A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, pp. 3018-3023 (1996)					
	AAI	R.A. Bebb, "Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, pp. 757-762 (1996)					
	LAA	C.J. Bagatell et al., "Comparison of a Gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens," <i>Journal of Clinical Endocrinology and Metabolism</i> , 77, No. 2, pp. 427-432 (1997)					
	AAK	M.C. Merrigiola et al., "An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men," Fertility and Sterility, 68, pp. 84-850 (1997)					
Wh	AAL	World Health Organization, "Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men," Fertility and Sterility, 65, pp. 84-850 (1997)					
	AAM	E: Nieschiag et al., "Aufgaben und Zi pp. 8-9 (1996)	ele der Andrologie – Grundlagen und klinik der rep	reductiven gesundheit des mannes,"			
RB	AAN	D.Buechter et al., "Clinical trial of tran Clinical Endocrinology & Metabolism,	nsdermal testosterone and oral levonorgestrel for r 84, No. 4, pp. 1244-1249 (1999)	nale contraception," The Journal of			
en	AAO	English Abstract of WO96/03131 date	ed 08FEB96				
PUB	AAP	World Health Organization, "Contraceptive efficacy of testosterone-induced azoospermia in normal men," <i>The Lancet</i> , 336, pp. 955-959 (1990)					
	AAQ						
Examiner Rachel W. Bennett Date Considered 12/19/17							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							